Incyte Corporation Release: Pivotal Phase 3 Data In Polycythemia Vera Show That Jakafi® (Ruxolitinib) Achieved Superior Disease Control Compared To Best Available Therapies

CHICAGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV). Ruxolitinib, compared to best available therapy (BAT), significantly improved hematocrit control (red blood cell volume) without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with uncontrolled PV -- those who are resistant to or intolerant of hydroxyurea (HU). Findings from the RESPONSE study are being presented in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago.

Help employers find you! Check out all the jobs and post your resume.